{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-057151","form_type":"8-K","ticker":null,"cik":"0001843762","company_name":"EQRx, Inc.","filed_at":"2023-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.148416+00:00","generated_at":"2026-06-15T14:21:30.294458+00:00","sec_items":["1.02","2.02","2.05","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"EQRx resets strategy, terminates two license deals, cuts 170 jobs, posts $82.6M Q1 loss","bullets":["Terminates license agreements with CStone (sugemalimab/nofazinlimab) and Lynk (EQ121 JAK-1 inhibitor); partners regain rights outside Greater China.","Approves restructuring: ~170 positions eliminated; estimated total restructuring costs $45M-$55M in 2023; expects annualized cash savings of at least $125M.","Q1 2023 net loss $82.6M vs net income $20.7M in Q1 2022; cash and investments $1.3B; expects year-end cash ~$1.1B.","Prioritizing lerociclib (CDK4/6 inhibitor) with Phase 3 trial in endometrial cancer; seeking partnerships for aumolertinib outside Greater China.","Plans to separate early-stage immune-inflammatory programs into new subsidiary and explore its path as an independent company."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-057151","json":"https://secwatch.observer/filing/0001104659-23-057151.json","markdown":"https://secwatch.observer/filing/0001104659-23-057151.md","text":"https://secwatch.observer/filing/0001104659-23-057151.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1843762/000110465923057151/0001104659-23-057151-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1843762/000110465923057151/tm2314964d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T14:21:30.294458+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"564269e43fc3d0cd501d2906ea4440f58d898a7d","claim":"EQRx, Inc. reported financial results for the first quarter ended March 31, 2023.","evidence_excerpt":"On May 8, 2023, EQRx issued a press release announcing its financial results for the first quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1843762/000110465923057151/0001104659-23-057151-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"739be0fadfbb2f4e128e60a811e9fb7e4d8030c7","claim":"EQRx, Inc. terminated Exclusive License Agreement with CStone Pharmaceuticals with CStone Pharmaceuticals valued at $150.0 million upfront non-refundable, non-creditable payment; additional potential milestone paymen (effective 2023-05-08).","evidence_excerpt":"Item 1.02 Termination of a Material Definitive Agreement. CStone Pharmaceuticals On May 8, 2023, EQRx, Inc. (EQRx) provided written notice to CStone Pharmaceuticals (CStone) of its termination of the Exclusive License Agreement dated October 26, 2020 between EQRx and CStone (as amended, the CStone Agreement), which termination will be effective in accordance with the terms of such agreement.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1843762/000110465923057151/0001104659-23-057151-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"CStone Pharmaceuticals"},{"label":"Value","value":"$150.0 million upfront non-refundable, non-creditable payment; additional potential milestone paymen"},{"label":"Effective","value":"2023-05-08"}],"fact_type":"material_agreement"},{"claim_id":"79d2487ec00fd81e10859beb13735b216a21710d","claim":"EQRx, Inc. terminated Exclusive License Agreement with Lynk Pharmaceuticals with Lynk Pharmaceutical (Hangzhou) Co., Ltd. valued at Upfront non-refundable, non-creditable payment; additional potential milestone payments up to $172.0 (effective 2023-05-08).","evidence_excerpt":"On May 8, 2023, EQRx provided written notice to Lynk Pharmaceutical (Hangzhou) Co., Ltd. (Lynk) of its termination of the Exclusive License Agreement dated April 1, 2020 between EQRx and Lynk Pharmaceuticals (as amended, the Lynk Agreement), which termination will be effective in accordance with the terms of such agreement.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1843762/000110465923057151/0001104659-23-057151-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Lynk Pharmaceutical (Hangzhou) Co., Ltd."},{"label":"Value","value":"Upfront non-refundable, non-creditable payment; additional potential milestone payments up to $172.0"},{"label":"Effective","value":"2023-05-08"}],"fact_type":"material_agreement"},{"claim_id":"11c1505a4a26e6a8414c197b52ecc663b44cd8e6","claim":"EQRx, Inc. announced a restructuring with charges of in the range of $45.0 million to $55.0 million (a decrease in headcount of approximately 170 positions).","evidence_excerpt":"a result of, or that are associated with, the other May 2023 strategic decisions. Therefore, EQRx currently estimates total restructuring costs for 2023 will be in the range of $45.0 million to $55.0 million. Each departing employee of EQRx has played an integral role in EQRx’s commitment to develop and commercialize innovative medicines for some of the most","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1843762/000110465923057151/0001104659-23-057151-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"in the range of $45.0 million to $55.0 million"},{"label":"Headcount","value":"a decrease in headcount of approximately 170 positions"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}